Rosalind Advisors’s CorMedix CRMD Stock Holding History

Rosalind Advisors’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-183,900	Closed	-$920K	–	36
2024 Q4	$920K	Sell	183,900 -516,100	-74%	-$5.15M	0.47%	26
2024 Q3	$3.64M	Buy	+700,000	New	+$3.79M	2.33%	15

Other funds holding CRMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $3.39B AUM 105.5% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Rosalind Advisors's CRMD Position: Q4 2024 in Review

Rosalind Advisors sold out of CorMedix (CRMD) in Q4 2024, closing a stake of 1,475,000 shares — an estimated $14.7M sold.

Rosalind Advisors first reported a position in CRMD in Q3 2024 and held it in 1 quarter. The position peaked at $11.9M in Q3 2024. 129 funds tracked by Wall St. Rank hold CRMD as of Q4 2024.

Rosalind Advisors reported no remaining CorMedix position as of Q4 2024 after selling out during the quarter.
Rosalind Advisors sold 1,475,000 CorMedix shares in Q4 2024, an estimated $14.7M.
Rosalind Advisors first reported a position in CorMedix in Q3 2024 and held it in 1 quarter.
Rosalind Advisors's CorMedix position peaked at $11.9M in Q3 2024.
129 funds tracked by Wall St. Rank held CorMedix as of Q4 2024.

Based on Rosalind Advisors's 13F filing for Q4 2024, filed 11 Feb 2025.